Pharmaceutical companies face unprecedented pressure as Trump's "most-favored nation" policy forces a global pricing recalibration, potentially more impactful than Medicare negotiations. Explore how industry leaders are responding with strategic price adjustments in this Trendline.
|
Access this Trendline from our sister publication Biopharma Dive for the latest developments on drug pricing, including:
|
-
Trump redoubles threats in attempt to strongarm drugmakers on prices
-
Lilly sends a drug price signal in response to Trump threats
-
Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO
|
|
This Trendline is independently produced by our journalists. The support of our sponsors makes this journalism possible. Want to learn about sponsorship opportunities? Contact us directly at advertising@industrydive.com.
|
|
|
|
